EGFR Resisters is a grass roots patient-driven community comprised of approximately 3000 members from over 75 countries. We are dedicated exclusively to changing EGFR Positive lung cancer into a manageable chronic disease.
Lung cancer patients with mutations in the EGFR gene represent a
significant number of patients diagnosed with non-small cell lung cancer.
Approximately 10-15% of patients with non-small cell lung cancer in the
United States and 35% in Asia have an EGFR positive mutation. In the U.S., more
than 20,000 people are diagnosed with EGFR positive lung cancer each
year.
We are working to increase the size of our EGFR Resisters community with
the assistance of advocacy groups and medical professionals. Our aim is
to use the strength of our collaboration to drive important research
questions and fund novel research and clinical trials.